Inhibition of gastrin secretion by pirenzepine (LS 519) in treatment of gastric ulcer.
The effects of pirenzepine on the serum gastrin levels in the basal state and in response to a liquid test meal were investigated in nine patients with gastric ulcer. Single-dose administration of the drug caused a significant decrease in the basal gastrin level and significant inhibition of the serum gastrin response. When measured 12 h after the end of drug treatment for 7 days, the serum gastrin levels in the basal state and in response to a test meal tended to be high, but the differences were not statistically significant.
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001570:Benzodiazepinones / Q000494:pharmacology* / Q000627:therapeutic use; D003864:Depression, Chemical; D005260:Female; D005755:Gastrins / Q000097:blood / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D010890:Pirenzepine; D011863:Radioimmunoassay; D013276:Stomach Ulcer / Q000188:drug therapy*; D013997:Time Factors
D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D005755:Gastrins; D010879:Piperazines; D010890:Pirenzepine